Ind-Swift Laboratories
INDSWFTLAB •NSE

Ind-Swift Laboratories

₹395.150.00 (0.00%)1D
1D
1W
1M
3M
6M
1Y
3Y
5Y
All
Create Stock SIPAutomate your investments in this
Overview
Technicals
News
Events

Performance

Today’s low
379.50
Today’s high
409.90
52 week low
87.15
52 week high
424.75
Open price
388.60
Previous close
395.15
Live volume
--
Lower circuit
316.15
Upper circuit
474.15

Fundamentals

Market Cap
₹3,437Cr
ROE
3.57%
P/E Ratio(TTM)
59.98
EPS(TTM)
6.59
P/B Ratio
2.48
Dividend Yield
0.00%
Industry P/E
37.66
Book Value
159.06
Debt to Equity
0.01
Face Value
10

Financial performance

Quarterly
Yearly
All Financials
JUN '26
₹199Cr
+15.75%
₹24.57Cr
+62.61%
050100150200
Jun '25
Sep '25
Dec '25
Mar '26
Jun '26
Revenue growthValue
1Y (TTM)+19%
3Y CAGR-18%
Profit growthValue
1Y (TTM)+184%
3Y CAGR-3%

About

For over 29 years, Ind-Swift Laboratories has established itself as a prominent global pharmaceutical brand, known for its dedicated and passionate efforts in the industry. With a strong legacy and financial health, the company is well-positioned to navigate future challenges and is committed to its focus on creating substantial value. A key part of its recent strategy was to completely repay its debt, freeing itself from financial constraints to focus on innovation and strategic growth. The company is now moving up the value chain by transitioning from Active Pharmaceutical Ingredients (APIs) into the high-value business of formulations, or finished medicines. To enhance its presence in this new business area, the company is amalgamating with its group company, Ind Swift Ltd, which has decades of formulation experience. This strategic pivot is backed by strong performance, with the company's revenue scaling from ₹1,185 crore in FY23 to ₹1,273 crore in FY24.;
CEO/MD
Sahil Munjal
Founded in
1995
NSE symbol
INDSWFTLAB

Shareholding pattern

Dec '25
Feb '26
Mar '26
Jun '26
Sep '26
Shareholder details

Similar stocks

StockMkt price (1D)52 week performanceMarket capP/E ratioP/B ratio
₹2,631.90
0.00 (--)
L
    H
    20,008.9429.515.94
    PfizerPFIZER
    ₹3,858.90
    0.00 (--)
    L
      H
      17,635.9823.994.2
      Natco PharmaNATCOPHARM
      ₹821.30
      0.00 (--)
      L
        H
        16,120.1014.081.54
        ₹999.30
        0.00 (--)
        L
          H
          15,940.3545.362.25
          Livesquawk •
          Ind-Swift Labs plans to file 400+ IP dossiers by FY27. This strategy aims to boost long-term, IP-led revenue visibility.
          Livesquawk •
          Ind Swift Lab forecasts revenue growth of 20–25% CAGR, targeting ₹1,200 crore by FY29. Current revenue stands at ₹636 crore, showing ambitious expansion plans.
          Livesquawk •
          Ind Swift Lab's CDMO partnerships with Viatris, Manx, and Arrotex are operational. These partnerships are projected to add ₹200–220 crore in revenue by FY27.
          Livesquawk •
          Ind Swift Laboratories approves sale of 10 acres in Punjab for ₹175M.
          2026
          10
          Aug
          Quarterly Result
          Release date
          28
          May
          Annual Result
          Release date
          31
          Jan
          Result
          Release date
          2025
          14
          Nov
          Quarterly Result
          Release date
          13
          Aug
          Quarterly Result
          Release date
          11
          Aug
          Annual Result
          Release date
          Events calendar
          View upcoming events in other stocks